logo
Rocket Doctor's Virtually-Enabled Emergency Department  Diversion Program Reduces Strain on Overwhelmed Hospitals

Rocket Doctor's Virtually-Enabled Emergency Department  Diversion Program Reduces Strain on Overwhelmed Hospitals

Vancouver, BC, July 31, 2025 (GLOBE NEWSWIRE) —
Treatment.com
AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') and its wholly owned digital health platform and marketplace, Rocket Doctor, are providing a scalable response to Canada's emergency department crisis with a data-backed diversion program. The program uses smart triage, provider infrastructure, and AI-enabled care to safely keep appropriate patients with low-acuity healthcare concerns out of overcrowded hospitals, while getting them the comprehensive out-patient care that they need, faster.
Across Canada, hospitals are facing unprecedented strain. Since 2019, emergency departments have experienced more than
1.14 million hours of closure
, the equivalent of 47,500 lost days of emergency care. Ontario and Alberta have been hit especially hard, with
rural ER closures and care disruptions
becoming a regular occurrence. This reality has left communities with few options and patients in critical need of safe, timely alternatives.
British Columbia is equally seeing regular ER closures throughout 2025, causing challenges for patients, healthcare systems and especially rural communities:
BC is not Alone – Rural ER Crisis across Canada – BC Rural Health Network
While in many cases a virtual-only system is not a replacement for in-person emergency care, Rocket Doctor's ED diversion program is helping to support hospitals and patients to fill a void in accessible care. The platform enables hospital systems to allow patients to self-select to reroute themselves to clinically appropriate, out-patient consultations, leveraging customized intake forms, real-time triage, and a flexible physician network, either from independent MDs on Rocket Doctor's platform, or the hospital's own staff.
At Georgian Bay General Hospital in Ontario, the results speak for themselves. Between June 2022 and December 2024, more than 3,065 patients have been successfully managed through MDs on Rocket Doctor's platform, with 97% of patients treated virtually and only 1% redirected to the ER. Patients waited an average of just 20 minutes to connect with a physician. The estimated system savings totaled $1.4 million, based on an average $475 cost per diverted ER visit multiplied by the total number of patients seen. All visits were covered under OHIP, with no additional fees to patients.
In Alberta, Rocket Doctor has seen similar success across its broader platform, with over 12,000 patients seen in the past 3 months alone, entirely funded by provincial health insurance. More than 98% of these visits were resolved without requiring in-person care, and less than 1% were sent to the ER.
'We see so many patients in our rural, remote and even urban communities going to ED, often when they recognize that they could be seen outside the hospital.' Said Dr. William Cherniak, CEO of Rocket Doctor. 'There has been a lot of good content from the Canadian Association of Emergency Physicians (CAEP) to recognize that we need to support patients to access healthcare where they see most appropriate. We often see patients choose an ED with low-acuity issues simply because of a lack of access to family doctors, or other accessible out-patient choices.'
By leveraging smart triage and other digital tools, Rocket Doctor's ED Diversion Program and broader platform pairs patients with the right physician based on their needs, empowering physicians to order labs, imaging, make specialist referrals, or escalate care to in-person options when clinically necessary (although rare). Patients can also rebook with the same physician to ensure continuity of care, improving outcomes and reducing unnecessary visits.
'We are filling that gap by empowering physicians in a team-based cloud-enabled model of care with technological support to work at the top of their license within their clinical competencies digitally.' said Dr. Cherniak. 'We're building a system that gives patients a smarter entry point and gives physicians the tools to work independently, safely, and efficiently.'
As staffing shortages and rural hospital disruptions continue to affect patients across Canada, Rocket Doctor and
Treatment.com
AI are offering hospitals and provincial systems a deployable, proven solution; one that reduces backlog, lowers system strain, and drives meaningful outcomes at scale.
About
Treatment.com
AI Inc.
Treatment.com
AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally,
Treatment.com
AI has built a comprehensive, personalized healthcare AI engine - the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support.
Treatment.com
AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at
www.treatment.com
or contact
info@treatment.com
.
About Rocket Doctor Inc.
Rocket Doctor is a technology-driven digital health platform and marketplace that is breaking down obstacles that limit access to quality, comprehensive and cost-effective healthcare. Our proprietary software equips doctors with the tools to run practices in virtual and hybridized in-person/virtual models of care, enabling them to provide tailored care to patients in rural and Northern communities across Canada and on Medicaid in the United States. Leveraging large language models, AI/ML and wireless medical devices, Rocket Doctor is bridging the healthcare divide, connecting patients to equitable and accessible virtual healthcare services regardless of age, location, or financial status.
To learn more about Rocket Doctor's platform and services, visit
www.rocketdoctor.ca
(Canada) or
www.rocketdoctor.io
(U.S.), or contact
media@rocketdoctor.io
.
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO,
Treatment.com
AI
Email:
ehamza@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Dr. Bill Cherniak, CEO, Rocket Doctor
Email:
bill@rocketdoctor.io
Media inquiries:
media@rocketdoctor.io
Cautionary Statement
This news release contains forward-looking statements that are based on
Treatment.com
AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although
Treatment.com
believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and
Treatment.com
undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Happy Belly Food Groups Heal Wellness QSR Announces the Signing of its Second Franchise Agreement for the Province of Quebec
Happy Belly Food Groups Heal Wellness QSR Announces the Signing of its Second Franchise Agreement for the Province of Quebec

Yahoo

time2 hours ago

  • Yahoo

Happy Belly Food Groups Heal Wellness QSR Announces the Signing of its Second Franchise Agreement for the Province of Quebec

Toronto, Ontario--(Newsfile Corp. - August 19, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands across Canada is pleased to announce that further to its 40-unit area development agreement for the province of Quebec signed on June 18th, 2025, and the announcement of its first signed franchise agreement on August 15th, it is pleased to announce that a second franchise agreement for Heal Wellness has been signed for the province of Quebec. Heal Wellness ("Heal"), a quick-service restaurant ("QSR") specializing in fresh smoothie bowls, açaí bowls, and smoothies. Happy Belly 1 To view an enhanced version of this graphic, please visit: "This latest agreement represents a continued momentum in Heal's national expansion, especially into Quebec and underscores the growing momentum of Happy Belly's portfolio of emerging brands. With the signing of our second franchisee in Quebec, Heal is rapidly solidifying its presence in the province, demonstrating our ability to successfully introduce and scale brands in new markets. Alongside Rosie's Burgers and Yolks Breakfast, this expansion reinforces Happy Belly's proven track record of building and strengthening emerging concepts across Canada, now making meaningful inroads into Quebec," said Sean Black, Chief Executive Officer of Happy Belly."Quebec represents a significant opportunity for Heal, and the addition of a second franchisee underscores the confidence entrepreneurs have in our brand and growth model. Our Quebec-based area developer partners bring deep expertise in launching and supporting brand operations, ensuring Heal's success in the province. This latest franchise agreement demonstrates the scalability of our franchise model and our commitment to building a truly national footprint for Heal Wellness. Our vision remains clear-to establish Heal Wellness as the leading acai bowl and smoothie brand in Canada." Happy Belly 2 To view an enhanced version of this graphic, please visit: "The Happy Belly portfolio has 616 retail locations under contract-spanning projects in development, under construction, or already open-our franchise pipeline is robust. By carefully selecting the right partners and prime real estate, we will maintain momentum and achieve our disciplined growth objectives through 2026. "We are just getting started," said Sean Heal Wellness Heal Wellness was founded with a passion and mission to provide quick, fresh wellness foods that support a busy and active lifestyle. We currently offer a diverse range of smoothie bowls and smoothies. We take pride in meticulously selecting every superfood ingredient on our menu to fuel the body, including acai smoothie bowls, smoothies, and super-seed grain bowls. Our smoothie bowls are crafted with real fruit and enriched with superfoods like acai, pitaya, goji berries, chia seeds, and more. FranchisingFor franchising inquiries please see or contact us at hello@ About Happy Belly Food GroupHappy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company") is a leader in acquiring and scaling emerging food brands across Canada. Happy Belly 3 To view an enhanced version of this graphic, please visit: Sean BlackCo-founder, Chief Executive Officer Shawn MonizCo-founder, Chief Operating Officer FOR FURTHER INFORMATION, PLEASE VISIT:www: or email hello@ you wish to contact us please call: 1-877-589-8805 Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management. Cautionary Note Regarding Forward-Looking Statements All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws. Forward-Looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include the future performance of Happy Belly and her subsidiaries. Forward-Looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the business plans for Happy Belly described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on To view the source version of this press release, please visit 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Say Goodbye to Itchy Skin: SilverCeuticals Launches Breakthrough FDA-Registered Eczema Therapy & Skin Relief Cream
Say Goodbye to Itchy Skin: SilverCeuticals Launches Breakthrough FDA-Registered Eczema Therapy & Skin Relief Cream

Associated Press

time3 hours ago

  • Associated Press

Say Goodbye to Itchy Skin: SilverCeuticals Launches Breakthrough FDA-Registered Eczema Therapy & Skin Relief Cream

The natural solution to skin irritation - Powered by science, nature, and silver. LINDON, UTAH / ACCESS Newswire / August 19, 2025 / SilverCeuticals Inc, a leader in advanced nano silver health and wellness solutions, is proud to announce the launch of its newest FDA-registered Over the Counter (OTC) drug product: Eczema Therapy & Skin Relief Cream. Designed to deliver fast, effective relief for irritated skin, this revolutionary formula combines FDA-approved colloidal oatmeal with SilverCeuticals' AG4O4 Nano Silver Therapy & Skin Relief Cream A bottle of SilverCeuticals Eczema Therapy & Skin Relief Cream Clinically backed, naturally soothing, and powerfully effective. Visible results may be seen in just 1-2 days. 'It's time for eczema relief products that actually work, without harsh chemicals,' said Dr. Keith Moeller, CEO of SilverCeuticals. 'This product is safe, highly moisturizing, and supports fast recovery for children and adults who suffer from eczema and other skin irritations. We've included ingredients that not only meet FDA standards but also align with the values of natural health practitioners.' This ultra-hydrating cream features a powerful blend of ingredients, including: Unlike many conventional treatments, this formulation is free from steroids, parabens, fragrances, and other harsh chemicals - making it ideal for sensitive skin. It also provides relief beyond eczema for other common skin issues, such as: Packaged in a TSA-compliant 3.4 oz. airless pump bottle, it's perfect for travel and daily use. 'One in five children experiences eczema and our goal is to eliminate their irritation and suffering without the harmful side effects. We believe healing should be fast, safe, and accessible.' added Dr. Moeller. 'After just two days, my son's eczema patches had nearly disappeared. Nothing has ever worked this fast and without steroids.' - Sarah L., mother of a 6-year-old eczema sufferer AG4O4 Nano Silver has been shown in lab studies to support the body's natural healing process and helps reduce inflammation at the source. Experience real relief! Order your first bottle today at Use the coupon code 'Heal' to receive a 15% discount at checkout. Also available through practitioners, professionals, and affiliates. For media or wholesale inquiries, contact SilverCeuticals at 385-212-4044. Contact InformationKirk Moeller CMO 8016364851 SOURCE: SilverCeuticals Inc press release

Coloplast A/S – Interim Financial Report, 9M 2024/25
Coloplast A/S – Interim Financial Report, 9M 2024/25

Business Upturn

time7 hours ago

  • Business Upturn

Coloplast A/S – Interim Financial Report, 9M 2024/25

By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store